

Department of Planning and Budget

2020 Fiscal Impact Statement

1. Bill Number: SB1074ER

House of Origin	<input type="checkbox"/> Introduced	<input type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
Second House	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input checked="" type="checkbox"/> Enrolled

2. Patron: McClellan

3. Committee: Passed both Houses.

4. Title: Schedule VI controlled substances; hypodermic syringes and needles; limited-use license.

5. Summary: Allows the Board of Pharmacy to issue a limited-use license for the purpose of dispensing Schedule VI controlled substances, excluding the combination of misoprostol and methotrexate, and hypodermic syringes and needles for the administration of prescribed controlled substances to a doctor of medicine, osteopathic medicine, or podiatry, a nurse practitioner, or a physician assistant, provided that such limited-use licensee is practicing at a nonprofit facility. The bill requires such nonprofit facilities to obtain a limited-use permit from the Board and comply with regulations for such a permit.

6. Budget Amendment Necessary: No.

7. Fiscal Impact Estimates: Minimal, see item #8.

8. Fiscal Implications: Any increase in workload for the Board of Pharmacy to promulgate regulations and issue limited-use licenses can be absorbed within existing resources.

9. Specific Agency or Political Subdivisions Affected: None.

10. Technical Amendment Necessary: No.

11. Other Comments: None.